Table 2.

Summary of treatment-related adverse events

Variable	Vorolanib + Pembro				Vorolanib + Nivo				All patients (n = 16)
	Vorolanib 300 mg + pembro (n = 3)		Vorolanib 400 mg + pembro (n = 6)		Vorolanib 300 mg + nivo (n = 4)		Vorolanib 400 mg + nivo (n = 3)
	All grades, n	Grade 3–4, n	All grades, n	Grade 3–4, n	All grades, n	Grade 3–4, n	All grades, n	Grade 3–4, n	All grades, n (%)	Grade 3–4, n (%)
Lymphopenia			3	1	2		2		7 (43.7%)	1 (6.2%)
Leukopenia			2	1	2	1	1		5 (31.2%)	2 (12.5%)
Anemia					1		1		2 (12.5%)
Neutropenia			2	2	2	2			4 (25.0%)	4 (25.0%)
Thrombocytopenia			2		1				3 (18.7%)
Fatigue	2		3						5 (31.2%)
ALT elevation			4	1	1				5 (31.2%)	1 (6.2%)
AST elevation			3	2*	1				4 (25.0%)	2 (12.5%)
ALP elevation			2	1					2 (12.5%)	1 (6.2%)
Myalgia			3		1				4 (25.0%)
Dysgeusia			1		1		1		3 (18.7%)
Hypertension	1		1	1					2 (12.5%)	1 (6.2%)
Proteinuria			3						3 (18.7%)
Hair color change			2						2 (12.5%)
Anorexia/weight loss					2				2 (12.5%)
Diarrhea					1		1	1	2 (12.5%)	1 (6.2%)
Hypothyroidism/TSH elevation			1				1		2 (12.5%)
Rectal hemorrhage				1*					1 (6.2%)	1 (6.2%)
Pancreatitis or amylase/lipase elevation				1		1			2 (12.5%)	2 (12.5%)
Skin Rash					1		1	1*	2 (12.5%)	1 (6.2%)
Peripheral sensory neuropathy			1		1				2 (12.5%)
Pruritis			1				1		2 (12.5%)

Data are number (n) and include percent (%) when indicated. Treatment-related adverse events experienced by two or more patients are listed in this table. Dose-limiting toxicities observed in 3 patients are also included and delineated by (*). All adverse events were assessed and reported according to the revised National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

ALP: alkaline phosphatase elevation, ALT alanine aminotransferase, AST aspartate aminotransferase, TSH thyroid stimulating hormone